Why were 2,187 Artiva Biotherapeutics (ARTV) shares disposed of at $4.00 per share?

The 2,187 shares at $4.00 per share were withheld by Artiva Biotherapeutics to satisfy income tax obligations triggered by the vesting of restricted stock unit awards. This tax-withholding disposition is coded as a Form 4 transaction but is not an open-market sale.

Artiva Biotherapeutics (ARTV) COO receives 117,300-share award with tax withholding

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. Chief Tech Operations Officer Christopher Horan reported equity compensation and a related tax withholding transaction in company stock. He received a grant of 117,300 shares of common stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. On the same date, 2,187 shares of common stock at a price of $4.00 per share were withheld by the company to cover income tax obligations arising from the vesting of restricted stock unit awards. After these transactions, Horan directly owned 300,452 shares of Artiva’s common stock.

Insider Trade Summary

Net Buyer: 115,113 shares

Net Buy 2 txns

Insider Horan Christopher

Role Chief Tech Operations Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	117,300	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,187	$4.00	$9K

Holdings After Transaction: Common Stock — 300,452 shares (Direct)

Footnotes (2)

F1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
F2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/18/2026 - 06:50 PM

FAQ

What insider transactions did Artiva Biotherapeutics (ARTV) report for Christopher Horan?

Artiva Biotherapeutics reported that Chief Tech Operations Officer Christopher Horan received a grant of 117,300 common shares as a restricted stock unit award. On the same date, 2,187 shares were withheld by the company to satisfy income tax obligations related to RSU vesting.

Was the Artiva Biotherapeutics (ARTV) Form 4 transaction a purchase or sale?

The Form 4 shows an equity award and a tax-related share withholding, not an open-market buy or sell. Horan acquired 117,300 shares via a restricted stock unit award and disposed of 2,187 shares withheld by the issuer to cover income taxes on vesting.

How many Artiva Biotherapeutics (ARTV) shares does Christopher Horan hold after the Form 4 transactions?

Following the reported transactions, Christopher Horan directly holds 300,452 shares of Artiva Biotherapeutics common stock. This figure reflects both the 117,300-share restricted stock unit award and the 2,187 shares withheld by the issuer for tax obligations tied to RSU vesting.

What is the nature of the 117,300 Artiva Biotherapeutics (ARTV) shares reported on the Form 4?

The 117,300 shares represent a restricted stock unit award granted under Artiva Biotherapeutics’ 2024 Equity Incentive Plan. These shares are compensation-related, granted to Chief Tech Operations Officer Christopher Horan, rather than shares bought on the open market or through a traditional purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horan Christopher

(Last)

(First)

(Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Tech Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2026		A		117,300⁽¹⁾	A	$0	302,639	D
Common Stock	02/15/2026		F		2,187⁽²⁾	D	$4	300,452	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR